Brief: Metacrine Reports Q4 2020 Financial Results
18/03/2021 10:43
March 18 (Reuters) - Metacrine Inc MTCR.O :
* METACRINE - INTERIM DATA FROM PHASE 2A TRIAL OF MET642 IN
NASH
PATIENTS ON-TRACK TO BE REPORTED IN Q4 OF 2021
* METACRINE - CASH, CASH EQUIVALENTS & SHORT-TERM
INVESTMENTS AS
OF DEC 31, 2020 WILL BE SUFFICIENT TO FUND ITS CURRENT OPERATING
PLAN THROUGH 2022
Source text for Eikon: ID:nGNX6jmqm8
Further company coverage: MTCR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Metacrine
See all newsMetacrine Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Metacrine - Filed Certificate Of Dissolution With Secretary Of State Of State Of Delaware To Effect Complete Liquidation And Dissolution Of Company
Brief: Metacrine Inc Common Stock Will Be Delisted From Nasdaq
Brief: Metacrine Inc- On Jan 31, Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
Brief: Metacrine CEO Preston Klassen Was Terminated From All Positions